Dazparda
Insulin aspart biosimilar developed by Gan & Lee Pharmaceuticals. Reference product NovoRapid (NovoLog in the United States).
About Dazparda
Dazparda is Gan & Lee's insulin aspart, approved in Europe in April 2026, the third insulin aspart biosimilar there. It followed Gan & Lee's insulin glargine, Ondibta, and was joined a month later by its insulin lispro.
Status by market
United States
Not listed by FDA.
European Union · Dazparda
European Medicines Agency and European CommissionApprovedUnited Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Not listed by CDSCO.
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Dazparda holds an approval, these are the other insulin aspart biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 2 | Biocon Biologics (Kirsty), Sanofi (Merilog / Insulin aspart Sanofi) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Gan & Lee Pharmaceuticals: Bysumlog, Ondibta.
Chronology
- EMAApr 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning insulin aspart biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant